Solid Tumors expressing MSLN
Showing 1 - 25 of >10,000
Advanced or Metastatic Solid Tumors Trial in Beijing (CD40 ligand expressing MSLN-CAR T cells, Albumin-bound paclitaxel,
Recruiting
- Advanced or Metastatic Solid Tumors
- CD40 ligand expressing MSLN-CAR T cells
- +2 more
-
Beijing, Beijing, ChinaKaichao Feng
Jan 19, 2023
Advanced Solid Tumor Trial in Beijing (aPD1-MSLN-CAR T Cells)
Not yet recruiting
- Advanced Solid Tumor
- αPD1-MSLN-CAR T Cells
-
Beijing, ChinaNational Cancer Center Cancer Hospital Chinese Academy of Medica
Jul 13, 2023
Solid Tumor Trial in Shanghai (aPD1-MSLN-CAR T cells)
Recruiting
- Solid Tumor
- αPD1-MSLN-CAR T cells
-
Shanghai, Shanghai, ChinaShanghai Mengchao Cancer Hospital
Oct 24, 2022
Solid Tumor, Adult, Colorectal Cancer, NSCLC Trial in United States (A2B694, xT CDx with HLA-LOH Assay)
Not yet recruiting
- Solid Tumor, Adult
- +19 more
- A2B694
- xT CDx with HLA-LOH Assay
-
Duarte, California
- +9 more
Sep 22, 2023
Mesothelin-positive Advanced Malignant Solid Tumors Trial (Anti-mesothelin CAR-T cells)
Not yet recruiting
- Mesothelin-positive Advanced Malignant Solid Tumors
- Anti-mesothelin CAR-T cells
- (no location specified)
Mar 13, 2023
Trial (MSLN STAR-T cells)
Not yet recruiting
- MSLN STAR-T cells
- (no location specified)
Apr 22, 2022
Her2-positive/Low-expression Urinary and Digestive Tract Tumors Trial in Beijing (BL-M07D1)
Not yet recruiting
- Her2-positive/Low-expression Urinary and Digestive Tract Tumors
-
Beijing, Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
Sep 8, 2023
Cancer Trial in Wuhan (RD133)
Recruiting
- Cancer
-
Wuhan, Hubei, ChinaTongji Hospital of Tongji Medical College, Huazhong University o
Apr 26, 2022
Colorectal Cancer Trial (CAR T cells)
Not yet recruiting
- Colorectal Cancer
- CAR T cells
- (no location specified)
Oct 11, 2021
Solid Tumor Trial in Nanjing (RD133)
Recruiting
- Solid Tumor
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Dec 8, 2021
Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma Trial in Australia (89Zr-TLX250, 177Lu-TLX250 and
Recruiting
- Solid Tumor, Adult
- +2 more
- 89Zr-TLX250
- 177Lu-TLX250 and Peposertib
-
North Ryde, New South Wales, Australia
- +4 more
May 22, 2023
HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and
Not yet recruiting
- HER2+ Advanced Breast Cancer
- Other Solid Tumors
- ADCC-R-Epo-R T-cells + Trastuzumab
- +2 more
- (no location specified)
Aug 31, 2023
HER2-expressing Advanced Solid Tumors Trial (SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor
Not yet recruiting
- HER2-expressing Advanced Solid Tumors
- SHR-A1811 combined with Pyrotinib.
- SHR-A1811 combined with other antitumor therapies
- (no location specified)
Aug 28, 2023
Advanced Solid Tumor Trial (SHR-4602 for injection)
Not yet recruiting
- Advanced Solid Tumor
- SHR-4602 for injection
- (no location specified)
Apr 6, 2023
Locally Advanced or Metastatic Solid Tumors Trial in Beijing (MSC-IFNa, Nab paclitaxel, Cyclophosphamide)
Recruiting
- Locally Advanced or Metastatic Solid Tumors
- MSC-IFNα
- +3 more
-
Beijing, ChinaDepartment of Biotherapeutic, Chinese PLA General Hospital
Jan 29, 2023
Solid Tumors Trial (TCR-T cells, Fludarabine, Cyclophosphamide Capsules)
Not yet recruiting
- Solid Tumors
- TCR-T cells
- +4 more
- (no location specified)
Dec 12, 2022
HER2 Expressing or Mutated Advanced Malignant Solid Tumors Trial in China (GQ1005)
Recruiting
- HER2 Expressing or Mutated Advanced Malignant Solid Tumors
-
Beijing, Beijing, China
- +19 more
Nov 23, 2023
Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant Trial run by the National
Not yet recruiting
- Malignant Pleural Mesotheliomas (Mpm)
- +4 more
- Cytoreductive surgery
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification Trial in San Antonio, Fairfax (ORM-5029)
Not yet recruiting
- HER2-positive Breast Cancer
- +3 more
-
San Antonio, Texas
- +1 more
Aug 22, 2022
Advanced Solid Tumors Trial in Shanghai, Chengdu (SHR-A1811, Fluzoparib Capsule)
Enrolling by invitation
- Advanced Solid Tumors
- SHR-A1811
- Fluzoparib Capsule
-
Shanghai, Shanghai, China
- +1 more
Jun 28, 2022
Advanced Solid Tumor Trial in Dallas (TCRT-ESO-A2)
Withdrawn
- Advanced Solid Tumor
- TCRT-ESO-A2
- (no location specified)
Aug 31, 2022
Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)
Completed
- Sarcoma
- +3 more
- Anti-GD2-CAR engineered T cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Solid Tumor Trial in Belgium, Netherlands, United Kingdom (SYD985 + Niraparib)
Active, not recruiting
- Solid Tumor
- SYD985 + Niraparib
-
Antwerp, Belgium
- +5 more
Jan 23, 2023